Literature DB >> 11924883

A dopamine D3 receptor partial agonist blocks the expression of conditioned activity.

Harinder Aujla1, Pierre Sokoloff, Richard J Beninger.   

Abstract

The partial dopamine D3 receptor agonist BP 897 attenuates cocaine seeking suggesting that BP 897 will attenuate conditioned activity to environmental stimuli paired with amphetamine. During conditioning, amphetamine (2.0 mg/kg) stimulated activity and co-treatment with BP 897 (1.0 mg/kg) had no effect. In the saline test, groups conditioned with amphetamine or amphetamine plus BP 897 showed conditioned activity. Treatment with BP 897 in the test following conditioning with saline produced no significant effect but following conditioning with amphetamine BP 897 blocked conditioned activity. Results extend previous findings that BP 897 attenuates responding for cocaine-paired stimuli to amphetamine-paired stimuli in a different paradigm and support the potential of BP 897 as a therapeutic agent for the prevention of drug seeking.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924883     DOI: 10.1097/00001756-200201210-00039

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  11 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

Review 2.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 3.  Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor.

Authors:  R J Beninger; T J Banasikowski
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

Review 4.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  Time-dependent effects of prazosin on the development of methamphetamine conditioned hyperactivity and context-specific sensitization in mice.

Authors:  André O White; Anthony S Rauhut
Journal:  Behav Brain Res       Date:  2014-01-31       Impact factor: 3.332

6.  A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice.

Authors:  Li Sun; Rui Song; Ying Chen; Ri-fang Yang; Ning Wu; Rui-bin Su; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

7.  Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors.

Authors:  Jeremy G Gilbert; Amy Hauck Newman; Eliot L Gardner; Charles R Ashby; Christian A Heidbreder; Arlene C Pak; Xiao-Qing Peng; Zheng-Xiong Xi
Journal:  Synapse       Date:  2005-07       Impact factor: 2.562

8.  Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Authors:  Henriette Francès; Maria Smirnova; Ludovic Leriche; Pierre Sokoloff
Journal:  Psychopharmacology (Berl)       Date:  2004-04-17       Impact factor: 4.530

9.  Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.

Authors:  Yang Lv; Rong-Rong Hu; Manyi Jing; Tai-Yun Zhao; Ning Wu; Rui Song; Jin Li; Gang Hu
Journal:  Acta Pharmacol Sin       Date:  2018-09-17       Impact factor: 6.150

10.  (±)VK4-40, a novel dopamine D3 receptor partial agonist, attenuates cocaine reward and relapse in rodents.

Authors:  Chloe J Jordan; Yi He; Guo-Hua Bi; Zhi-Bing You; Jianjing Cao; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Br J Pharmacol       Date:  2020-09-17       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.